egg-derived split-virus seasonal influenza vaccine

The egg-derived split-virus seasonal influenza vaccine is a licensed, commercially available biologic used for the active immunization against seasonal influenza. Produced using traditional embryonated chicken egg-based manufacturing technology, the vaccine consists of purified, inactivated, split influenza virus antigens, primarily hemagglutinin (HA) and neuraminidase (NA). It is designed to stimulate the human immune system to produce hemagglutination inhibition antibodies against specific influenza A and B strains. In clinical development, this vaccine type frequently serves as the active control or reference standard for evaluating the safety and immunogenicity of next-generation vaccines, such as those derived from cell-culture (e.g., Vero cells) or recombinant technologies.

Other names

inactivated split-virion influenza vaccineegg-based seasonal influenza vaccinesplit-virus seasonal influenza vaccine